Payment & Shipping Terms:
|Appearance:||White Crystal Powder||Other Name:||LEFLUNOMIDE|
|Melting Point:||165-166°C||CAS NO.:||75706-12-6|
75706-12-6 Leflunomide Medicine Raw Materials For Pharmaceuticals
Leflunomide is Raw Material for immunosuppressive disease-modifying antirheumatic drug (DMARD),used in active moderate to severe rheumatoid arthritis and psoriatic arthritis.
High quality raw material Leflunomide
|Common Name: Leflunomide|
|Category: Pharmaceutical meterial|
|Chemical Name: 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazole carboxamide|
|Packing: 1kg/5kg in aluminium tin . 20kg in cardboard drum.|
|CAS No.: 75706-12-6|
Leflunomide is an immunosuppressive drug that inhibits T and B cell responses. Leflunomide is an inhibitor of Cox-2, of tyrosine phosphorylation (tyrosine kinase), of DHODH (dihydroorotate dehydrogenase), an enzyme for de novopyrimidine synthesis, and of TNF-dependent NF-κB activation. The physiological activity of leflunomide is attributed mainly to its metabolite A77 1726.
Mechanism of Action:
Leflunomide is an immunomodulatory drug that achieves its effects by inhibiting the mitochondrial enzymedihydroorotate dehydrogenase (DHODH), which plays a key role in the de novo synthesis of uridine monophosphate(rUMP), which is required for the synthesis of DNA and RNA. Hence, leflunomide inhibits the reproduction of rapidly dividing cells, especially lymphocytes.
The inhibition of human DHODH by teriflunomide, the active metabolite of leflunomide, occurs at levels (approximately 600 nM) that are achieved during treatment of rheumatoid arthritis (RA).Teriflunomide also inhibits several tyrosine kinases.Teriflunomide prevents the expansion of activated and autoimmune lymphocytes by interfering with their cell cycle progression while nonlymphoid cells are able to use another pathway to make their ribonucleotides by use of salvage pyrimidine pathway, which makes them less dependent onde novo synthesis.Teriflunomide also has antiviral effects against numerous viruses including CMV, HSV1 and the BK virus, which it achieves by inhibiting viral replication by interfering with nucleocapsid tegumentation and hence virion assembly.
Its principle dose-limiting side effects are liver damage, lung disease and immunosuppression.The most common side effects (occurring in >1% of those treated with it) are, in approximately descending order of frequency: diarrhea, respiratory tract infections, hair loss, high blood pressure, rash, nausea, bronchitis, headache, abdominal pain, abnormal liver function tests, back pain,indigestion, urinary tract infection, dizziness, infection, joint disorder, itchiness, weight loss, loss of appetite, cough, gastroenteritis, pharyngitis, stomatitis, tenosynovitis, vomiting, weakness, allergic reaction, chest pain, dry skin, eczema,paraesthesia, pneumonia, rhinitis, synovitis, cholelithiasis andshortness of breath.
|Risedronate sodium||cas no.115436-72-1|
|zoledronic acid||cas no.165800-06-6|
1kg/Aluminum foil bag
1kg/ Aluminium Tin
25kg/ Aluminum Drum
Usually within 3 working days after confirming the payment.